Making Sense of Preventive Therapies for Migraine
A Managed Care Perspective
Friday, October 23, 2020 | 9:00 AM - 10:30 AM EDT

    LIVE Virtual Symposium

    Participants can access this live virtual event on Friday, October 23, 9:00 - 10:00 AM EDT

    Activity Overview

    This program will review the burden of frequent migraine and the importance of using the most effective preventive migraine therapies as early as possible. The presentations will review our understanding of both established and emerging therapies for the prevention of migraine. The goal will be to provide an understanding of the clinical data for preventive migraine therapies and a perspective on how this information could be used in the managed care setting.

    Speakers
    • Amaal J. Starling, MD
      Moderator
      Associate Professor of Neurology
      Mayo Clinic Alix School of Medicine
      Consultant
      Department of Neurology
      Mayo Clinic Arizona
      Scottsdale, Arizona
    • Dawn C. Buse, PhD
      Speaker
      Clinical Professor
      Department of Neurology
      Albert Einstein College of Medicine
      Assistant Professor
      Clinical Health Psychology Doctoral Program
      Ferkauf Graduate School of Psychology Yeshiva University
      New York, New York
    • YuQian Liu, PharmD
      Speaker
      Director
      Specialty Clinical Solutions
      Magellan RX Management
      Middletown, Rhode Island
    Program Friday, October 23, 2020
    • 9:00 AM
    • Welcome and Introductions
    • 9:05 AM
    • Migraine Criteria, Prevalence, and Burden
      Dawn C. Buse, PhD
    • 9:30 AM
    • Established Approaches for Migraine Prevention
      Amaal J. Starling, MD
    • 9:55 AM
    • The Future Is Now: The Clinical Use of CGRP Monoclonal Antibodies
      YuQian Liu, PharmD
    • 10:20 AM
    • Q&A
    Learning Objectives
    • Have increased knowledge regarding the
      • Data relating to the burden associated with frequent migraine
      • Limitations of established oral therapies for the prevention of migraine
      • Factors that differentiate calcitonin gene-related peptide (CGRP) monoclonal antibodies for the prevention of migraine
      • Appropriate sequencing of available preventive migraine therapies
    Target Audience
    Goal Statement
    Credits Available
    • 1.50
    • For Physicians
    • 1.50
    • For Pharmacists
    Accreditation Statement


    Your home!
    Online
    Medscape is in partnership with:
    Medscape is in partnership with:
    Supported by an independent educational grant from
    Lundbeck, Inc.